Affiliation:
1. Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad-382 481, Gujarat, India
Abstract
Background:
Numerous studies suggest that non-steroidal anti-inflammatory drugs reduce cancer
cell proliferation, progression, angiogenesis, apoptosis, and invasiveness.
Objective:
The current study focuses on the evaluation of novel mefenamic acid derivatives for the treatment of
hepatocellular carcinoma.
Methods:
Derivatives were subjected to molecular modeling for prediction of pharmacological activity using
software, followed by synthesis and in vitro assay. In in vivo study, disease was induced with N-Nitrosodiethylamine
followed by 2-acetylaminofluorene orally for 2 weeks. After 12 weeks of induction, treatment was given for a
period of one week. At the end of the treatment, determination of liver weight, a number of nodules, biochemical
parameters, immunohistochemistry, histopathology, and gene expression studies, were carried out.
Results:
Based on molecular docking score for PDGF-α (Platelet-Derived Growth Factor) and IC50 values in
HepG2 cell line study, JS-PFA was selected for the in vivo study where JS-PFA showed a statistically significant
reduction in a number of nodules and liver weight. Protective role of JS-PFA has been observed in tumorspecific
markers like α-fetoprotein, carcinoembryonic antigen, and lactate dehydrogenase levels. The JS-PFA
has shown a significant reduction in PDGF-α levels as well as liver markers and total bilirubin levels. Histopathological
analysis also showed a protective effect. The results of immunohistochemical analysis of P53 and
down-regulation of vascular endothelial growth factor and matrix metalloproteinases-9 genes suggest that derivative
inhibits PDGF mediated tumor growth and leads to apoptosis, inhibition of angiogenesis, and metastasis.
Conclusion:
The effectiveness of JS-PFA in our studies suggests targeting PDGF by COX 2 inhibitor can serve
as a novel treatment strategy for the treatment of HCC.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Pharmacology,Molecular Medicine
Reference33 articles.
1. Tinkle C.L.; Haas-Kogan D.; Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012,6,207-219
2. Shariff M.I.F.; Cox I.J.; Gomaa A.I.; Khan S.A.; Gedroyc W.; Taylor-Robinson S.D.; Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 2009,3(4),353-367
3. Cervello M.; Foderàa D.; Florena A.M.; Soresi M.; Tripodo C.; D’Alessandro N.; Montalto G.; Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol 2005,11(30),4638-4643
4. McGary E.C.; Weber K.; Mills L.; Doucet M.; Lewis V.; Lev D.C.; Fidler I.J.; Bar-Eli M.; Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002,8(11),3584-3591
5. Wei T.; Zhang L-N.; Lv Y.; Ma X-Y.; Zhi L.; Liu C.; Ma F.; Zhang X-F.; Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma. Oncotarget 2014,5(21),10307-10317
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献